Myocardial Ischemia - Pipeline Review, H1 2018

  • ID: 4464768
  • Report
  • 65 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Angionetics Inc
  • Bayer AG
  • Cellmid Ltd
  • CohBar Inc
  • NoNO Inc
  • Omniox Inc
  • MORE
Myocardial Ischemia - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Ischemia - Pipeline Review, H1 2018, provides an overview of the Myocardial Ischemia (Cardiovascular) pipeline landscape.

Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris), neck or jaw pain, shoulder or arm pain, clammy skin, shortness of breath and nausea and vomiting. Myocardial ischemia can be caused by conditions such as coronary artery disease (atherosclerosis), blood clot, coronary spasm and severe illnesses. The factors that may increase the risk of developing myocardial ischemia include tobacco, diabetes, high blood pressure, high blood cholesterol or triglyceride levels, lack of physical activity, obesity and family history.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Myocardial Ischemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Myocardial Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Myocardial Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourcedfrom the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Ischemia (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Myocardial Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myocardial Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myocardial Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Ischemia (Cardiovascular)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myocardial Ischemia (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myocardial Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Angionetics Inc
  • Bayer AG
  • Cellmid Ltd
  • CohBar Inc
  • NoNO Inc
  • Omniox Inc
  • MORE
Introduction

The Publisher's Report Coverage

Myocardial Ischemia - Overview

Myocardial Ischemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Myocardial Ischemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Myocardial Ischemia - Companies Involved in Therapeutics Development

Angionetics Inc

Bayer AG

Cellmid Ltd

CohBar Inc

Lixte Biotechnology Holdings Inc

NoNO Inc

Omniox Inc

Pathfinder Cell Therapy Inc

Myocardial Ischemia - Drug Profiles

AB-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alferminogene tadenovec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-606583 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Myocardial Ischemia, Renal Failure and Type 1 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMK-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DT-010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Humanin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMX-4.80 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMC-6 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sirolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Myocardial Ischemia Reperfusion Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TRPM7 for Oncology, Ophthalmology, Cardiovascular and Central nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myocardial Ischemia - Dormant Projects

Myocardial Ischemia - Discontinued Products

Myocardial Ischemia - Product Development Milestones

Featured News & Press Releases

Jan 09, 2017: Angionetics Research Head Authors Scientific American Article on Therapeutic Angiogenesis as Potential New Treatment Approach for Ischemic Heart Disease

Sep 12, 2016: Angionetics' Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease

May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities

Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum

Sep 03, 2014: Taxus Cardium to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City

Aug 13, 2014: Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Journal of Cardiovascular Pharmacology

Jun 12, 2014: Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention

Jan 27, 2014: Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings

May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy

Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease

Oct 25, 2012: Cytori Announces Japanese Approval For Clinical Studies Of Cardiovascular And Chronic Liver Disease Cell Therapy

Mar 20, 2012: Cardium Therapeutics Initiates Generx Phase III Clinical Registration Study

Jun 15, 2011: Cardium Therapeutics's Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance For Phase III Registration Clinical Study For Coronary Artery Disease

Nov 03, 2010: Cardium Awarded Grant Under QTDP Program

Dec 08, 2006: Cardium's Generx Advances To Phase III Following Meeting With FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Myocardial Ischemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Myocardial Ischemia - Pipeline by Angionetics Inc, H1 2018

Myocardial Ischemia - Pipeline by Bayer AG, H1 2018

Myocardial Ischemia - Pipeline by Cellmid Ltd, H1 2018

Myocardial Ischemia - Pipeline by CohBar Inc, H1 2018

Myocardial Ischemia - Pipeline by Lixte Biotechnology Holdings Inc, H1 2018

Myocardial Ischemia - Pipeline by NoNO Inc, H1 2018

Myocardial Ischemia - Pipeline by Omniox Inc, H1 2018

Myocardial Ischemia - Pipeline by Pathfinder Cell Therapy Inc, H1 2018

Myocardial Ischemia - Dormant Projects, H1 2018

Myocardial Ischemia - Dormant Projects, H1 2018 (Contd..1), H1 2018

Myocardial Ischemia - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Myocardial Ischemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Angionetics Inc
  • Bayer AG
  • Cellmid Ltd
  • CohBar Inc
  • Lixte Biotechnology Holdings Inc
  • NoNO Inc
  • Omniox Inc
  • Pathfinder Cell Therapy Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll